Clinical trial · Interventional
Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer
Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer.
NCT02407912CI-TRIAL-00019869unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the effect and toxicity of intrapleural administration of hypertonic cisplatin for malignant pleural effusion in patients with non-small-cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pleural Effusion, Malignant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cisplatin
- description
- 75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
- interventionNames
- Drug: cisplatin
- type
- NO_INTERVENTION
- label
- Control
- description
- No intervention was applied.
Primary outcomes (1)
- measure
- overall response rate
- timeFrame
- one month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Cytologically proven and previously untreated malignant pleural effusion of Non-small-cell Lung Cancer; * An Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1; * A leucocyte count of≥4000µl; * A platelet count of≥100000µl; * A normal creatinine level; * Serum glutamic oxaloacetic transaminase/glutamic pyruvic transaminase levels of no more than twice the upper limit of normal; * Survival time ≥12 weeks. Exclusion Criteria: * Previously treated malignant pleural effusion; * Pericardial effusion； * Pregnant； * Uncontrolled hypertension or diabetes； * Liver cihrosis.
References
Publications (0)
Data not yet available
No reference posted for this study.